TW201722477A - 藉由組合療法治療固態或淋巴腫瘤的方法 - Google Patents

Info

Publication number

TW201722477A

TW201722477A TW105133787A TW105133787A TW201722477A TW 201722477 A TW201722477 A TW 201722477A TW 105133787 A TW105133787 A TW 105133787A TW 105133787 A TW105133787 A TW 105133787A TW 201722477 A TW201722477 A TW 201722477A

Authority

TW

Taiwan

Prior art keywords

tumor

agent

infectious agent

administration

administered

Prior art date

2015-10-19

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 612
• 239000007787 solid Substances 0.000 title claims abstract description 136
• 238000000034 method Methods 0.000 title abstract description 235
• 230000001926 lymphatic effect Effects 0.000 title abstract description 11
• 238000002648 combination therapy Methods 0.000 title description 7
• 239000012678 infectious agent Substances 0.000 claims abstract description 383
• 239000002955 immunomodulating agent Substances 0.000 claims abstract description 155
• 229940121354 immunomodulator Drugs 0.000 claims abstract description 155
• 239000000203 mixture Substances 0.000 claims abstract description 139
• 210000004881 tumor cell Anatomy 0.000 claims abstract description 71
• 230000002584 immunomodulator Effects 0.000 claims abstract description 19
• 239000003795 chemical substances by application Substances 0.000 claims description 577
• 230000002519 immonomodulatory effect Effects 0.000 claims description 469
• 208000019420 lymphoid neoplasm Diseases 0.000 claims description 136
• 239000003446 ligand Substances 0.000 claims description 94
• 230000003308 immunostimulating effect Effects 0.000 claims description 91
• 230000001900 immune effect Effects 0.000 claims description 83
• 229940045513 CTLA4 antagonist Drugs 0.000 claims description 73
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 67
• 239000012190 activator Substances 0.000 claims description 64
• 238000002560 therapeutic procedure Methods 0.000 claims description 52
• 238000011200 topical administration Methods 0.000 claims description 52
• 102000039446 nucleic acids Human genes 0.000 claims description 48
• 108020004707 nucleic acids Proteins 0.000 claims description 48
• 150000007523 nucleic acids Chemical class 0.000 claims description 48
• 239000003814 drug Substances 0.000 claims description 47
• 241000700605 Viruses Species 0.000 claims description 45
• 238000001959 radiotherapy Methods 0.000 claims description 45
• 238000011282 treatment Methods 0.000 claims description 44
• 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 20
• 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 20
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 108010050904 Interferons Proteins 0.000 claims description 14
• 102000014150 Interferons Human genes 0.000 claims description 12
• 229940079322 interferon Drugs 0.000 claims description 12
• 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 claims description 11
• 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims description 10
• 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 claims description 10
• -1 CCL4 Proteins 0.000 claims description 10
• 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 claims description 10
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 10
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 10
• 108010065805 Interleukin-12 Proteins 0.000 claims description 8
• 102000013462 Interleukin-12 Human genes 0.000 claims description 8
• 241000894006 Bacteria Species 0.000 claims description 7
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 7
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 7
• 108010002350 Interleukin-2 Proteins 0.000 claims description 7
• 102000000588 Interleukin-2 Human genes 0.000 claims description 7
• 102000002698 KIR Receptors Human genes 0.000 claims description 7
• 108010043610 KIR Receptors Proteins 0.000 claims description 7
• 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 7
• 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 7
• 102000002689 Toll-like receptor Human genes 0.000 claims description 6
• 108020000411 Toll-like receptor Proteins 0.000 claims description 6
• 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 5
• 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 5
• 102100038078 CD276 antigen Human genes 0.000 claims description 5
• 101710185679 CD276 antigen Proteins 0.000 claims description 5
• 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 5
• 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 5
• 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims description 5
• 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 5
• 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 5
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 5
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 5
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 5
• 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 5
• 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 5
• 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 5
• 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 5
• 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims description 5
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 5
• 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 5
• 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 5
• 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 5
• 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 5
• 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 5
• 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 5
• 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 5
• 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 5
• 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 5
• DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 5
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
• 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
• 101150013553 CD40 gene Proteins 0.000 claims 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
• 102000017578 LAG3 Human genes 0.000 claims 1
• 101150030213 Lag3 gene Proteins 0.000 claims 1
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
• 102100033117 Toll-like receptor 9 Human genes 0.000 claims 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
• 238000011275 oncology therapy Methods 0.000 abstract 1
• 239000003112 inhibitor Substances 0.000 description 179
• 244000309459 oncolytic virus Species 0.000 description 98
• 238000002347 injection Methods 0.000 description 93
• 239000007924 injection Substances 0.000 description 93
• 210000001519 tissue Anatomy 0.000 description 86
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 76
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 76
• 241000701161 unidentified adenovirus Species 0.000 description 75
• 210000004027 cell Anatomy 0.000 description 71
• 206010005003 Bladder cancer Diseases 0.000 description 70
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 69
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 66
• 201000005112 urinary bladder cancer Diseases 0.000 description 66
• 230000003442 weekly effect Effects 0.000 description 65
• 108090000623 proteins and genes Proteins 0.000 description 60
• 201000011510 cancer Diseases 0.000 description 57
• 230000002401 inhibitory effect Effects 0.000 description 56
• 102000004169 proteins and genes Human genes 0.000 description 56
• 235000018102 proteins Nutrition 0.000 description 55
• 239000002245 particle Substances 0.000 description 54
• 206010027476 Metastases Diseases 0.000 description 51
• 230000009401 metastasis Effects 0.000 description 51
• 229960005386 ipilimumab Drugs 0.000 description 47
• 229940124597 therapeutic agent Drugs 0.000 description 44
• 102000019298 Lipocalin Human genes 0.000 description 41
• 108050006654 Lipocalin Proteins 0.000 description 41
• 239000012270 PD-1 inhibitor Substances 0.000 description 38
• 239000012668 PD-1-inhibitor Substances 0.000 description 38
• 101710138750 Transcription factor E2F1 Proteins 0.000 description 38
• 229940121655 pd-1 inhibitor Drugs 0.000 description 38
• 239000013603 viral vector Substances 0.000 description 37
• 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 36
• 102000050313 human E2F1 Human genes 0.000 description 36
• 102000015696 Interleukins Human genes 0.000 description 34
• 108010063738 Interleukins Proteins 0.000 description 34
• 108700005077 Viral Genes Proteins 0.000 description 34
• 230000000174 oncolytic effect Effects 0.000 description 34
• 230000029812 viral genome replication Effects 0.000 description 33
• 230000003612 virological effect Effects 0.000 description 33
• 239000000090 biomarker Substances 0.000 description 32
• 230000001270 agonistic effect Effects 0.000 description 29
• 239000000427 antigen Substances 0.000 description 29
• 108091007433 antigens Proteins 0.000 description 29
• 102000036639 antigens Human genes 0.000 description 29
• 206010006187 Breast cancer Diseases 0.000 description 27
• 230000001394 metastastic effect Effects 0.000 description 26
• 206010061289 metastatic neoplasm Diseases 0.000 description 26
• 102000019034 Chemokines Human genes 0.000 description 25
• 108010012236 Chemokines Proteins 0.000 description 25
• 201000001441 melanoma Diseases 0.000 description 25
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 24
• 208000026310 Breast neoplasm Diseases 0.000 description 23
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 23
• 241000282414 Homo sapiens Species 0.000 description 22
• 239000002773 nucleotide Substances 0.000 description 22
• 125000003729 nucleotide group Chemical group 0.000 description 22
• 206010039491 Sarcoma Diseases 0.000 description 21
• 208000014829 head and neck neoplasm Diseases 0.000 description 20
• 230000026683 transduction Effects 0.000 description 19
• 201000010099 disease Diseases 0.000 description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
• 238000010361 transduction Methods 0.000 description 18
• 208000006265 Renal cell carcinoma Diseases 0.000 description 17
• LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 description 16
• 206010027406 Mesothelioma Diseases 0.000 description 16
• 201000010536 head and neck cancer Diseases 0.000 description 16
• 239000000523 sample Substances 0.000 description 16
• 108091026890 Coding region Proteins 0.000 description 15
• 101150075174 E1B gene Proteins 0.000 description 15
• 208000003174 Brain Neoplasms Diseases 0.000 description 14
• 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 14
• 206010061535 Ovarian neoplasm Diseases 0.000 description 14
• 210000001744 T-lymphocyte Anatomy 0.000 description 14
• 239000000556 agonist Substances 0.000 description 14
• 230000027455 binding Effects 0.000 description 14
• 210000000232 gallbladder Anatomy 0.000 description 14
• 230000002601 intratumoral effect Effects 0.000 description 14
• 239000003623 enhancer Substances 0.000 description 13
• 206010046766 uterine cancer Diseases 0.000 description 13
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 12
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 12
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 12
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 12
• 206010060862 Prostate cancer Diseases 0.000 description 12
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 12
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 12
• 230000003993 interaction Effects 0.000 description 12
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 239000012275 CTLA-4 inhibitor Substances 0.000 description 11
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 11
• 206010033128 Ovarian cancer Diseases 0.000 description 11
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 11
• 208000024770 Thyroid neoplasm Diseases 0.000 description 11
• 208000009956 adenocarcinoma Diseases 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 230000004083 survival effect Effects 0.000 description 10
• 201000009030 Carcinoma Diseases 0.000 description 9
• 206010009944 Colon cancer Diseases 0.000 description 9
• 108091006020 Fc-tagged proteins Proteins 0.000 description 9
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 9
• 206010025323 Lymphomas Diseases 0.000 description 9
• 239000012271 PD-L1 inhibitor Substances 0.000 description 9
• 230000002238 attenuated effect Effects 0.000 description 9
• 208000006990 cholangiocarcinoma Diseases 0.000 description 9
• 230000002779 inactivation Effects 0.000 description 9
• 229940047122 interleukins Drugs 0.000 description 9
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 9
• 229940121656 pd-l1 inhibitor Drugs 0.000 description 9
• 206010041823 squamous cell carcinoma Diseases 0.000 description 9
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 8
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 8
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 8
• 206010041067 Small cell lung cancer Diseases 0.000 description 8
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 8
• 210000003719 b-lymphocyte Anatomy 0.000 description 8
• 210000004443 dendritic cell Anatomy 0.000 description 8
• 239000012634 fragment Substances 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• 238000012239 gene modification Methods 0.000 description 8
• 230000005017 genetic modification Effects 0.000 description 8
• 235000013617 genetically modified food Nutrition 0.000 description 8
• 210000002865 immune cell Anatomy 0.000 description 8
• 230000028993 immune response Effects 0.000 description 8
• 208000020816 lung neoplasm Diseases 0.000 description 8
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 8
• 201000002528 pancreatic cancer Diseases 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 208000000587 small cell lung carcinoma Diseases 0.000 description 8
• 150000003384 small molecules Chemical class 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 206010044412 transitional cell carcinoma Diseases 0.000 description 8
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 8
• 238000002619 cancer immunotherapy Methods 0.000 description 7
• 229960003301 nivolumab Drugs 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 208000025421 tumor of uterus Diseases 0.000 description 7
• 229940055760 yervoy Drugs 0.000 description 7
• 229940123189 CD40 agonist Drugs 0.000 description 6
• 108091033409 CRISPR Proteins 0.000 description 6
• 206010008342 Cervix carcinoma Diseases 0.000 description 6
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• 102000004889 Interleukin-6 Human genes 0.000 description 6
• 108091054437 MHC class I family Proteins 0.000 description 6
• 102000043129 MHC class I family Human genes 0.000 description 6
• 108091005685 RIG-I-like receptors Proteins 0.000 description 6
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 6
• 208000002495 Uterine Neoplasms Diseases 0.000 description 6
• 201000010881 cervical cancer Diseases 0.000 description 6
• 239000013068 control sample Substances 0.000 description 6
• 229950009791 durvalumab Drugs 0.000 description 6
• 230000000694 effects Effects 0.000 description 6
• 201000010175 gallbladder cancer Diseases 0.000 description 6
• 201000007487 gallbladder carcinoma Diseases 0.000 description 6
• 102000046157 human CSF2 Human genes 0.000 description 6
• 239000003022 immunostimulating agent Substances 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 201000010260 leiomyoma Diseases 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 230000005855 radiation Effects 0.000 description 6
• 208000013076 thyroid tumor Diseases 0.000 description 6
• 208000023747 urothelial carcinoma Diseases 0.000 description 6
• 208000024719 uterine cervix neoplasm Diseases 0.000 description 6
• 239000013598 vector Substances 0.000 description 6
• YQYGGOPUTPQHAY-KIQLFZLRSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccccc1)NC(=O)C(CCCCNN[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)[C@H](C)O)C(C)C)[C@H](C)O YQYGGOPUTPQHAY-KIQLFZLRSA-N 0.000 description 5
• 206010005949 Bone cancer Diseases 0.000 description 5
• 208000018084 Bone neoplasm Diseases 0.000 description 5
• 108010029697 CD40 Ligand Proteins 0.000 description 5
• 102100032937 CD40 ligand Human genes 0.000 description 5
• 241000709687 Coxsackievirus Species 0.000 description 5
• 241000991587 Enterovirus C Species 0.000 description 5
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 5
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
• 102000008070 Interferon-gamma Human genes 0.000 description 5
• 108010074328 Interferon-gamma Proteins 0.000 description 5
• 241000186779 Listeria monocytogenes Species 0.000 description 5
• 241000712079 Measles morbillivirus Species 0.000 description 5
• 241000711386 Mumps virus Species 0.000 description 5
• 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 5
• 241000700618 Vaccinia virus Species 0.000 description 5
• 241000711975 Vesicular stomatitis virus Species 0.000 description 5
• ONVRFFJRASWLTG-UHFFFAOYSA-N [(1-amino-2-naphthalen-1-ylethylidene)amino] morpholine-4-carboxylate Chemical compound C=1C=CC2=CC=CC=C2C=1CC(N)=NOC(=O)N1CCOCC1 ONVRFFJRASWLTG-UHFFFAOYSA-N 0.000 description 5
• 238000001574 biopsy Methods 0.000 description 5
• 230000030833 cell death Effects 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 230000003325 follicular Effects 0.000 description 5
• 229960003130 interferon gamma Drugs 0.000 description 5
• 201000007270 liver cancer Diseases 0.000 description 5
• 208000014018 liver neoplasm Diseases 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 208000037841 lung tumor Diseases 0.000 description 5
• 210000001165 lymph node Anatomy 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 229960002621 pembrolizumab Drugs 0.000 description 5
• 230000002093 peripheral effect Effects 0.000 description 5
• 208000023958 prostate neoplasm Diseases 0.000 description 5
• 238000011301 standard therapy Methods 0.000 description 5
• 230000004936 stimulating effect Effects 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 201000002510 thyroid cancer Diseases 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 208000017604 Hodgkin disease Diseases 0.000 description 4
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
• 208000008839 Kidney Neoplasms Diseases 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 4
• 108091054438 MHC class II family Proteins 0.000 description 4
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
• 241000837158 Senecavirus A Species 0.000 description 4
• 241000700584 Simplexvirus Species 0.000 description 4
• 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 230000004611 cancer cell death Effects 0.000 description 4
• 239000002975 chemoattractant Substances 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 208000023965 endometrium neoplasm Diseases 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 210000003128 head Anatomy 0.000 description 4
• 229960002751 imiquimod Drugs 0.000 description 4
• DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
• 210000000822 natural killer cell Anatomy 0.000 description 4
• 230000000683 nonmetastatic effect Effects 0.000 description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• 239000005020 polyethylene terephthalate Substances 0.000 description 4
• 229920000139 polyethylene terephthalate Polymers 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 238000011277 treatment modality Methods 0.000 description 4
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 4
• 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 description 3
• 108091023037 Aptamer Proteins 0.000 description 3
• 208000003950 B-cell lymphoma Diseases 0.000 description 3
• 206010055113 Breast cancer metastatic Diseases 0.000 description 3
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 3
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
• 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 3
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 3
• 102100035793 CD83 antigen Human genes 0.000 description 3
• 238000010354 CRISPR gene editing Methods 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• 241000287828 Gallus gallus Species 0.000 description 3
• 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 3
• 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
• 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 description 3
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
• 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 3
• 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 3
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 3
• 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 3
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 3
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
• 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 3
• 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 description 3
• 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 description 3
• 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 description 3
• 101000843562 Homo sapiens Transcription factor HES-4 Proteins 0.000 description 3
• 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 3
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
• 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 3
• 102100031347 Metallothionein-2 Human genes 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 108091033773 MiR-155 Proteins 0.000 description 3
• 108700011259 MicroRNAs Proteins 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 206010057190 Respiratory tract infections Diseases 0.000 description 3
• 108091027967 Small hairpin RNA Proteins 0.000 description 3
• 108020004459 Small interfering RNA Proteins 0.000 description 3
• 108091061980 Spherical nucleic acid Proteins 0.000 description 3
• 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 3
• 206010042971 T-cell lymphoma Diseases 0.000 description 3
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
• 238000010459 TALEN Methods 0.000 description 3
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
• 102100030774 Transcription factor HES-4 Human genes 0.000 description 3
• 206010046798 Uterine leiomyoma Diseases 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
• 210000000612 antigen-presenting cell Anatomy 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 210000001124 body fluid Anatomy 0.000 description 3
• 239000010839 body fluid Substances 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 238000002591 computed tomography Methods 0.000 description 3
• 230000000139 costimulatory effect Effects 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 230000003412 degenerative effect Effects 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 229940126546 immune checkpoint molecule Drugs 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 230000001678 irradiating effect Effects 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 238000009115 maintenance therapy Methods 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 239000002679 microRNA Substances 0.000 description 3
• 201000005962 mycosis fungoides Diseases 0.000 description 3
• 208000007538 neurilemmoma Diseases 0.000 description 3
• 208000029974 neurofibrosarcoma Diseases 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 238000002271 resection Methods 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
• 239000002924 silencing RNA Substances 0.000 description 3
• 239000004055 small Interfering RNA Substances 0.000 description 3
• 208000000649 small cell carcinoma Diseases 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 108010045815 superoxide dismutase 2 Proteins 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000001052 transient effect Effects 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• 108010082808 4-1BB Ligand Proteins 0.000 description 2
• 206010001233 Adenoma benign Diseases 0.000 description 2
• 101150051188 Adora2a gene Proteins 0.000 description 2
• 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 241000711404 Avian avulavirus 1 Species 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 229940125565 BMS-986016 Drugs 0.000 description 2
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
• 102100027207 CD27 antigen Human genes 0.000 description 2
• 102100025221 CD70 antigen Human genes 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 201000000274 Carcinosarcoma Diseases 0.000 description 2
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
• 208000009798 Craniopharyngioma Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 206010014967 Ependymoma Diseases 0.000 description 2
• 102100031351 Galectin-9 Human genes 0.000 description 2
• 101710121810 Galectin-9 Proteins 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• 108090000353 Histone deacetylase Proteins 0.000 description 2
• 102100038720 Histone deacetylase 9 Human genes 0.000 description 2
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
• 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
• 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 108010000521 Human Growth Hormone Proteins 0.000 description 2
• 102000002265 Human Growth Hormone Human genes 0.000 description 2
• 239000000854 Human Growth Hormone Substances 0.000 description 2
• 241001135569 Human adenovirus 5 Species 0.000 description 2
• 102100034980 ICOS ligand Human genes 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000003810 Interleukin-18 Human genes 0.000 description 2
• 108090000171 Interleukin-18 Proteins 0.000 description 2
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• 206010024612 Lipoma Diseases 0.000 description 2
• 102000009151 Luteinizing Hormone Human genes 0.000 description 2
• 108010073521 Luteinizing Hormone Proteins 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
• 241000186359 Mycobacterium Species 0.000 description 2
• 108010042215 OX40 Ligand Proteins 0.000 description 2
• YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 2
• 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 102000003743 Relaxin Human genes 0.000 description 2
• 108090000103 Relaxin Proteins 0.000 description 2
• 101150036449 SIRPA gene Proteins 0.000 description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 2
• 229940126302 TTI-621 Drugs 0.000 description 2
• 102000011923 Thyrotropin Human genes 0.000 description 2
• 108010061174 Thyrotropin Proteins 0.000 description 2
• 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
• 229960005305 adenosine Drugs 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 210000000013 bile duct Anatomy 0.000 description 2
• 210000005013 brain tissue Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 229920006317 cationic polymer Polymers 0.000 description 2
• 238000002659 cell therapy Methods 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 208000012106 cystic neoplasm Diseases 0.000 description 2
• 230000002380 cytological effect Effects 0.000 description 2
• 239000000412 dendrimer Substances 0.000 description 2
• 229920000736 dendritic polymer Polymers 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 229940056913 eftilagimod alfa Drugs 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000002357 endometrial effect Effects 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 238000001125 extrusion Methods 0.000 description 2
• 206010016629 fibroma Diseases 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 230000005931 immune cell recruitment Effects 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 229960001438 immunostimulant agent Drugs 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 230000001861 immunosuppressant effect Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000002721 intensity-modulated radiation therapy Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 239000002085 irritant Substances 0.000 description 2
• 231100000021 irritant Toxicity 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 206010024627 liposarcoma Diseases 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 229940040129 luteinizing hormone Drugs 0.000 description 2
• 210000002751 lymph Anatomy 0.000 description 2
• 208000003747 lymphoid leukemia Diseases 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 230000005291 magnetic effect Effects 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
• 230000015654 memory Effects 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• 208000037819 metastatic cancer Diseases 0.000 description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 230000000955 neuroendocrine Effects 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 210000004923 pancreatic tissue Anatomy 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• 210000003695 paranasal sinus Anatomy 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 208000024724 pineal body neoplasm Diseases 0.000 description 2
• 238000002616 plasmapheresis Methods 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000002203 pretreatment Methods 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 210000001938 protoplast Anatomy 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 229960003614 regadenoson Drugs 0.000 description 2
• LZPZPHGJDAGEJZ-AKAIJSEGSA-N regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 description 2
• 210000003289 regulatory T cell Anatomy 0.000 description 2
• 210000005084 renal tissue Anatomy 0.000 description 2
• 201000006845 reticulosarcoma Diseases 0.000 description 2
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 210000004872 soft tissue Anatomy 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 206010042863 synovial sarcoma Diseases 0.000 description 2
• 229940126625 tavolimab Drugs 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
• 229950005972 urelumab Drugs 0.000 description 2
• 230000009790 vascular invasion Effects 0.000 description 2
• ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
• 101150096316 5 gene Proteins 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 229940125431 BRAF inhibitor Drugs 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 206010073062 Biphasic mesothelioma Diseases 0.000 description 1
• 206010006417 Bronchial carcinoma Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
• 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
• 206010065859 Congenital fibrosarcoma Diseases 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000007067 DNA methylation Effects 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
• 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 108010003471 Fetal Proteins Proteins 0.000 description 1
• 102000004641 Fetal Proteins Human genes 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
• 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 201000005618 Glomus Tumor Diseases 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
• 208000002125 Hemangioendothelioma Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 description 1
• 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 1
• 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 210000005131 Hürthle cell Anatomy 0.000 description 1
• 108091058560 IL8 Proteins 0.000 description 1
• 102100026818 Inhibin beta E chain Human genes 0.000 description 1
• 102000002746 Inhibins Human genes 0.000 description 1
• 108010004250 Inhibins Proteins 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 102000003816 Interleukin-13 Human genes 0.000 description 1
• 102000003812 Interleukin-15 Human genes 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 102000049772 Interleukin-16 Human genes 0.000 description 1
• 101800003050 Interleukin-16 Proteins 0.000 description 1
• 108050003558 Interleukin-17 Proteins 0.000 description 1
• 102000013691 Interleukin-17 Human genes 0.000 description 1
• 102100030703 Interleukin-22 Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 102000000646 Interleukin-3 Human genes 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000000743 Interleukin-5 Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102100021592 Interleukin-7 Human genes 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000000585 Interleukin-9 Human genes 0.000 description 1
• 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 1
• 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• 206010062038 Lip neoplasm Diseases 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 241001372913 Maraba virus Species 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 102100031789 Myeloid-derived growth factor Human genes 0.000 description 1
• 206010066948 Myxofibrosarcoma Diseases 0.000 description 1
• 206010028767 Nasal sinus cancer Diseases 0.000 description 1
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
• 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• 208000010505 Nose Neoplasms Diseases 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 description 1
• 241000282322 Panthera Species 0.000 description 1
• 208000037168 Papillary Follicular Carcinoma Diseases 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 206010033963 Parathyroid tumour Diseases 0.000 description 1
• 206010064666 Peritoneal perforation Diseases 0.000 description 1
• 208000000360 Perivascular Epithelioid Cell Neoplasms Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 108010003044 Placental Lactogen Proteins 0.000 description 1
• 239000000381 Placental Lactogen Substances 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 206010035603 Pleural mesothelioma Diseases 0.000 description 1
• 229920001100 Polydextrose Polymers 0.000 description 1
• DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 108010076181 Proinsulin Proteins 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 102100024819 Prolactin Human genes 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 238000003559 RNA-seq method Methods 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 241001632234 Senecavirus Species 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• 102000008063 Small Heat-Shock Proteins Human genes 0.000 description 1
• 108010088928 Small Heat-Shock Proteins Proteins 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 210000000447 Th1 cell Anatomy 0.000 description 1
• 210000000068 Th17 cell Anatomy 0.000 description 1
• 210000004241 Th2 cell Anatomy 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 201000000170 Thyroid lymphoma Diseases 0.000 description 1
• 108010002321 Tight Junction Proteins Proteins 0.000 description 1
• 102000000591 Tight Junction Proteins Human genes 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010045515 Undifferentiated sarcoma Diseases 0.000 description 1
• 206010046799 Uterine leiomyosarcoma Diseases 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 208000002938 adenomyoma Diseases 0.000 description 1
• 201000007348 adult fibrosarcoma Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 108010035879 albumin-bilirubin complex Proteins 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 201000007434 ampulla of Vater carcinoma Diseases 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 238000002583 angiography Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 229960003852 atezolizumab Drugs 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229950002916 avelumab Drugs 0.000 description 1
• 206010061691 benign mesothelioma Diseases 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 201000009036 biliary tract cancer Diseases 0.000 description 1
• 208000020790 biliary tract neoplasm Diseases 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 238000011243 body radiation therapy Methods 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 208000011825 carcinoma of the ampulla of vater Diseases 0.000 description 1
• 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 description 1
• 210000004970 cd4 cell Anatomy 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 201000010276 collecting duct carcinoma Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000010968 computed tomography angiography Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 229950005026 dapirolizumab pegol Drugs 0.000 description 1
• 108010048522 dapirolizumab pegol Proteins 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical group O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
• 238000005553 drilling Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000004043 dyeing Methods 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 201000000330 endometrial stromal sarcoma Diseases 0.000 description 1
• 208000029179 endometrioid stromal sarcoma Diseases 0.000 description 1
• 238000001839 endoscopy Methods 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 208000010932 epithelial neoplasm Diseases 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 238000002710 external beam radiation therapy Methods 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 206010049444 fibromatosis Diseases 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013373 food additive Nutrition 0.000 description 1
• 239000002778 food additive Substances 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 238000009499 grossing Methods 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 231100000234 hepatic damage Toxicity 0.000 description 1
• 210000002989 hepatic vein Anatomy 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229940099552 hyaluronan Drugs 0.000 description 1
• KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000008088 immune pathway Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 210000005008 immunosuppressive cell Anatomy 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 229950009034 indoximod Drugs 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 108010074108 interleukin-21 Proteins 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000002642 intravenous therapy Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 201000007785 kidney angiomyolipoma Diseases 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 201000006721 lip cancer Diseases 0.000 description 1
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 208000010033 lipoblastoma Diseases 0.000 description 1
• 230000008818 liver damage Effects 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 208000017830 lymphoblastoma Diseases 0.000 description 1
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 201000010117 malignant biphasic mesothelioma Diseases 0.000 description 1
• 208000014699 malignant epithelioid mesothelioma Diseases 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 208000024407 malignant pericardial mesothelioma Diseases 0.000 description 1
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
• 208000021937 marginal zone lymphoma Diseases 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 201000003731 mucosal melanoma Diseases 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 208000009091 myxoma Diseases 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 208000037830 nasal cancer Diseases 0.000 description 1
• 208000018066 neoplasm of oropharynx Diseases 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 208000028732 neoplasm with perivascular epithelioid cell differentiation Diseases 0.000 description 1
• 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
• 238000009206 nuclear medicine Methods 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 201000007052 paranasal sinus cancer Diseases 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 238000002727 particle therapy Methods 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229960005547 pelareorep Drugs 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 201000004266 pericardial mesothelioma Diseases 0.000 description 1
• 238000012831 peritoneal equilibrium test Methods 0.000 description 1
• 201000002513 peritoneal mesothelioma Diseases 0.000 description 1
• 201000005207 perivascular epithelioid cell tumor Diseases 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 210000002706 plastid Anatomy 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 239000001259 polydextrose Substances 0.000 description 1
• 229940035035 polydextrose Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229960000688 pomalidomide Drugs 0.000 description 1
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
• 210000003240 portal vein Anatomy 0.000 description 1
• 238000012636 positron electron tomography Methods 0.000 description 1
• 238000012877 positron emission topography Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 238000007781 pre-processing Methods 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 208000030266 primary brain neoplasm Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 229940034080 provenge Drugs 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 206010073065 sarcomatoid mesothelioma Diseases 0.000 description 1
• 208000018964 sebaceous gland cancer Diseases 0.000 description 1
• 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 208000028647 spindle cell neoplasm Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000013179 statistical model Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 201000008759 sweat gland cancer Diseases 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000002942 systemic radioisotope therapy Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
• 201000009657 thyroid sarcoma Diseases 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• 210000001578 tight junction Anatomy 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
• 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
• 208000025444 tumor of salivary gland Diseases 0.000 description 1
• 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
• 230000005760 tumorsuppression Effects 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 201000001496 urethra transitional cell carcinoma Diseases 0.000 description 1
• 201000005290 uterine carcinosarcoma Diseases 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 238000009941 weaving Methods 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1